Wolfe Research initiated coverage of Avantor with a Peer Perform rating. The company appears positioned for a rebound to mid-single-digit revenue growth and continued margin expansion once the BioPharma end market improves, the analyst tells investors in a research note. The firm added that downside risk seems relatively limited.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AVTR:
- Avantor price target raised by $2 at UBS, here’s why
- Avantor price target raised by $3 at Barclays, here’s why
- Avantor upgraded to Outperform at TD Cowen following Investor Day event
- TD Cowen gets more bullish on Avantor, upgrades shares
- Avantor® Hosts Investor Day, Announces New Strategic Operating Model to Drive Growth and Productivity